In this talk, we highlight epigenomics as a dynamic regulatory layer beyond genetics and demonstrate how minimally invasive liquid biopsies can provide multimodal biomarker readouts.
We first introduce our expanded portfolio, which now extends beyond cfDNA methylation to encompass chromatin and circulating nucleosome quantification, as well as comprehensive cfRNA profiling from liquid biopsy derived material. Building on this, we present real-world case studies demonstrating how cfDNA methylation can be leveraged for treatment response monitoring. We also illustrate how circulating nucleosomes and their histone PTMs can be used to assess epidrug effects and support the optimization of clinical trial decision-making. Finally, we show how comprehensive cfRNA-based transcriptomic profiling can be applied to cancer diagnostics.
Throughout, we emphasize the value of integrating multiple epigenomic readouts, combined with AI/ML analytics, to enhance mechanistic insight, improve biomarker performance for diagnostic applications including early detection, disease classification, and risk stratification, and ultimately accelerate translational research and drug development.
Key Topics Include:
- Hologic Diagenode empowers biomarker discovery and drug development through advanced epigenomic profiling and AI/ML-driven bioinformatics.
- Our newly expanded portfolio extends beyond cfDNA methylation to encompass chromatin and circulating nucleosome quantification, as well as transcriptomics via comprehensive cfRNA profiling from liquid biopsy-derived material.
- We present real-world case studies illustrating how epigenomic approaches can be applied to treatment response monitoring, assessment of drug efficacy, and diagnostic applications.
Resources
Presenters
Biopharma Business Development Manager
EMEA
Hologic Diagenode
Scientific Liaison Manager
EMEA and Life Sciences
Hologic Diagenode
Production Partner
Diagenode
